TUB.BR Stock - Financière de Tubize S.A.
Unlock GoAI Insights for TUB.BR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $13,257 | N/A | $8,151 | N/A | N/A |
| Gross Profit | $-2,223,346 | $-2,029,585 | $-1,819,919 | $-1,497,046 | N/A |
| Gross Margin | -16771.1% | N/A | -22327.6% | N/A | N/A |
| Operating Income | $-2,235,975 | $-2,143,974 | $-1,822,783 | $-1,540,101 | $-1,125,000 |
| Net Income | $90.10M | $88.15M | $85.17M | $83.60M | $260.52M |
| Net Margin | 679673.6% | N/A | 1044901.1% | N/A | N/A |
| EPS | $2.02 | $1.98 | $1.91 | $1.88 | $5.85 |
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
Visit WebsiteEarnings History & Surprises
TUB.BREPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 18, 2026 | — | — | — | — |
Q3 2025 | Aug 2, 2025 | — | $2.15 | — | — |
Q1 2025 | Mar 22, 2025 | — | $-0.06 | — | — |
Q3 2024 | Jul 25, 2024 | — | $2.09 | — | — |
Q1 2024 | Mar 16, 2024 | — | $-0.07 | — | — |
Q3 2023 | Jul 29, 2023 | — | $2.05 | — | — |
Q1 2023 | Feb 27, 2023 | — | $-1.33 | — | — |
Q2 2022 | Jun 30, 2022 | — | $3.25 | — | — |
Q4 2021 | Dec 31, 2021 | — | $3.94 | — | — |
Q2 2021 | Jun 30, 2021 | — | $4.60 | — | — |
Q4 2020 | Dec 31, 2020 | — | $2.94 | — | — |
Q2 2020 | Jun 30, 2020 | — | $2.91 | — | — |
Q4 2019 | Dec 30, 2019 | — | $1.00 | — | — |
Q2 2019 | Jun 29, 2019 | — | $3.31 | — | — |
Q4 2018 | Dec 31, 2018 | — | $1.97 | — | — |
Q2 2018 | Jun 30, 2018 | — | $4.43 | — | — |
Q4 2017 | Dec 31, 2017 | — | $2.96 | — | — |
Q2 2017 | Jun 30, 2017 | — | $3.46 | — | — |
Q4 2016 | Dec 31, 2016 | — | $1.68 | — | — |
Q2 2016 | Jun 30, 2016 | — | $2.39 | — | — |
Latest News
Frequently Asked Questions about TUB.BR
What is TUB.BR's current stock price?
What is the analyst price target for TUB.BR?
What sector is Financière de Tubize S.A. in?
What is TUB.BR's market cap?
Does TUB.BR pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to TUB.BR for comparison